*Time:* October 11, 7:30 p.m.–recess; October 12, 8 a.m.–recess; October 13, 8 a.m.–adjournment.

*Place:* Hampshire Hotel, 1310 New Hampshire Avenue, N.W., Washington, DC 20036.

*Contact Person:* Dr. Paul Sheehy, Scientific Review Administrator, National Institutes of Health, Federal Building, Room 9C–10, Bethesda, MD 20892, (301) 496–9223.

*Name of Committee:* Neurological Disorders Program Project Review A Committee.

*Date:* October 25–27, 1995.

*Time:* October 25, 7:30 p.m.–recess; October 26, 8:30 a.m.–recess; October 27, 8:30 a.m.–adjournment.

*Place:* Bethesda Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Dr. Katherine Woodbury, Scientific Review Administrator, National Institutes of Health, Federal Building, Room 9C–14, Bethesda, MD 20892, (301) 496–9223.

*Name of Committee:* Training Grant and Career Development Review Committee.

*Date:* November 8–10, 1995.

*Time:* November 8, 9 a.m.–recess; November 9, 8:30 a.m.–recess; November 10, 8:30 a.m.–adjournment.

*Place:* Hyatt Islandia, San Diego's Mission Bay, 1441 Quivira Road, San Diego, CA 92109–7898.

*Contact Person:* Dr. Alfred Gordon, Scientific Review Administrator, National Institutes of Health, Federal Building, Room 9C–14, Bethesda, MD 20892, (301) 496–9223.

(Catalog of Federal Domestic Assistance Program No. 93.853, Clinical Research Related to Neurological Disorders; No. 93.854, Biological Basis Research in the Neurosciences)

Dated: July 24, 1995.

**Susan K. Feldman,**

*Committee Management Officer, National Institutes of Health.*

[FR Doc. 95–18531 Filed 7–27–95; 8:45 am]

**BILLING CODE 4140–01–M**

## Division of Research Grants; Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* August 8, 1995.

*Time:* 4:00 p.m.

*Place:* NIH, Rockledge II, Room 4208, Telephone Conference.

*Contact Person:* Dr. Anita Weinblatt, Scientific Review Administrator, 6701 Rockledge Drive, Room 4208, Bethesda, MD 20892, (301) 435–1224.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* August 10, 1995.

*Time:* 2:30 p.m.

*Place:* NIH, Rockledge II, Room 4150, Telephone Conference.

*Contact Person:* Dr. Marcia Litwack, Scientific Review Administrator, 6701 Rockledge Drive, Room 4150, Bethesda, MD 20892, (301) 435–1719.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* August 14, 1995.

*Time:* 1:00 p.m.

*Place:* NIH, Rockledge II, Room 4200, Telephone Conference.

*Contact Person:* Dr. Gilbert Meier, Scientific Review Administrator, 6701 Rockledge Drive, Room 4200, Bethesda, MD 20892, (301) 435–1219.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* August 15, 1995.

*Time:* 10:00 a.m.

*Place:* NIH, Rockledge II, Room 4150, Telephone Conference.

*Contact Person:* Dr. Marcia Litwack, Scientific Review Administrator, 6701 Rockledge Drive, Room 4150, Bethesda, MD 20892, (301) 435–1719.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets of commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 24, 1995.

**Susan K. Feldman,**

*Committee Management Officer, NIH.*

[FR Doc. 95–18537 Filed 7–27–95; 8:45 am]

**BILLING CODE 4140–01–M**

## Prospective Grant of Exclusive License: Mouse Monoclonal Antibodies Specific for Normal Primate Tissue, Malignant Human Cultured Cell Lines and Human Tumors

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in U.S. Patent 5,242,813, U.S. Patent Applications 08/051,133 and 08/363,203 and corresponding foreign patent applications entitled ''Mouse Monoclonal Antibodies Specific For Normal Primate Tissue, Malignant Human Cultured Cell Lines and Human Tumors'' to Pharmacia, S.P.A. of Milano, Itlay. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The present invention includes three murine monoclonal antibodies (MAb), B1, B3 and B5. These antibodies react strongly with the Lewis Y blood group antigen on many human solid tumors but weakly with normal human tissues. MAb B3 reacts strongly with 10% of transitional cell carcinomas of the bladder, 75% of adenocarcinomas of the colon, 70% of adenocarcinomas of the lung, 65% with adenocarcinomas of the prostrate, 40% of squamous cell carcinomas of the lung and 25% of large cell carcinomas. MAb B3 reacts heterogeneously with 70% of breast carcinomas. Several important characteristics of this antibody make it an ideal candidate for further development: (1) Its strong and uniform reactivity with many human solid carcinomas; (2) its limited reactivity with normal tissues; (3) its expression on both human and monkey tissues will allow for predictive preclinical toxicology studies in monkeys. Additionally, these antibodies, when incorporated as the targeting element of an immunotoxin, have been shown to allow efficient entry of toxin agents into cells. These antibodies should be useful in the diagnosis and treatment of some forms of cancer.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Raphe Kantor, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804. Telephone: (301)